InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.037 -0.015 (-28.85%)+
Announcement
Release
26 Feb 2026 6:05PM
Price at Release
$0.052
Full Release
download
Summary
Emyria Limited's half-year financial report for the period ending 31 December 2025 highlights significant revenue growth and strategic expansions. Revenue increased by 136% to $1,554,497, driven by the expansion of its national Empax clinic network and insurer-funded treatments. However, the company reported a post-tax loss of $2,374,782, attributed to investments in infrastructure and workforce scaling. Key achievements in the period include a nationwide roll-out of Medibank's funding agreement, which now covers treatment programs for mental health conditions, and government payer access for veteran treatments. Emyria's strategic focus remains on expanding its clinic footprint and reinforcing its growth platform for mental health care. The company ended the period with a strengthened balance sheet following a significant institutional placement.
Key Points
  • Emyria Limited reported a total revenue of $1,554,497 for the half-year ended 31 December 2025, showing a 136% increase from the prior year.
  • The company's loss after tax for the same period was $2,374,782, which reflects investments in national expansion and increased clinical workforce.
  • Emyria expanded its Empax clinic network, with operations now across Western Australia, Queensland, and Victoria.
  • Key milestones include an expanded agreement with Medibank and secured government payer access with the Department of Veterans’ Affairs.
  • The company completed an $8.0 million institutional placement to support its national clinic rollout.
  • Emyria was recognized with the National Outstanding Clinic of the Year Award and the Wesfarmers Wellbeing Platinum Award.
  • At 31 December 2025, Emyria had a cash balance of $10,502,022.
  • The company is focusing on a capital-light growth platform for advanced mental health care in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.